Reta glucagon-like peptide-1 (GLP-1) receptor agonists provide a groundbreaking approach to diabetes management. These innovative medications operate by mimicking the natural actions of GLP-1, a hormone released by the gut in response to consumption. By triggering GLP-1 receptors in the pancreas, these agents boost insulin release and suppress gluc

The burgeoning landscape of novel treatments for metabolic management has seen the rise of both retatrutide and tirzepatide, both dual mechanism agonists targeting the GLP-1 and GIP receptors. While sharing a comparable therapeutic goal – improving glycemic control and promoting substantial weight decrease – they exhibit intriguing contrasts in